With BMS Set To Join, What Next For CAR-T Market?
Outpatient Use Will Be Key
CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?
You may also be interested in...
The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.
GSK has filed its anti-BCMA agent with the FDA after full Phase II DREAMM-2 data showed an overall response rate of 31% in patients with heavily pre-treated multiple myeloma.
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.